VJOncology is committed to improving our service to you

ASCO 2017 | Encorafenib in a combination regimen for BRAF melanoma

VJOncology is committed to improving our service to you

Paolo Ascierto

Paolo Ascierto, MD, from Istituto Nazionale Tumori, Napoli, Italy, discusses the results from a Phase Ib/II dose-escalation study evaluating triple combination therapy with a BRAF (encorafenib), MEK (binimetinib), and CDK 4/6 (ribociclib) inhibitor in patients with BRAF V600-mutant solid tumors and melanoma (NCT01820364). A few disappointing findings, such as insignificant differences in response rates between the triplet combination in comparison to a dual BRAF-MEK inhibitor regimen, as well as serious side effects associated with the regimen, such as liver toxicity, are elaborated here. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter